SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 3, 2006
Cytyc Corporation
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 0-27558 | | 02-0407755 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
| 250 Campus Drive, Marlborough, MA | | 01752 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (508) 263-2900
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01.Other Events
On October 3, 2006, Cytyc Corporation (“Cytyc”) issued a press release announcing that, with regard to Cytyc’s all cash tender offer to acquire Vision Systems Limited (“Vision”), it has:
| • | | completed dispatch of its bidder’s statement to acquire Vision for A$3.25 per outstanding share; |
| • | | lodged an application to the Australian Takeovers Panel to set aside Ventana Medical Systems, Inc.’s acquisition of 12% of Vision’s shares; and |
| • | | written to the Australian Competition & Consumer Commission outlining its continuing concern about the negative competition consequences that an acquisition of Vision by Ventana would have on Australia’s pathology and healthcare markets. |
The description of the press release set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed pursuant to Item 8.01:
| | |
| Exhibit No. | | Description |
| 99.1 | | Press release, dated October 3, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| CYTYC CORPORATION |
| |
| By: | | /s/ Patrick J. Sullivan |
| | Patrick J. Sullivan Chairman, Chief Executive Officer, and President |
Date: October 5, 2006
EXHIBIT INDEX
| | |
| Exhibit No. | | Description |
| 99.1 | | Press release, dated October 3, 2006. |
